AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

Inclusion Criteria: * Histologically or cytologically documented invasive epithelial ovarian, primary peritoneal, or fallopian tube cancer * Radiographically documented disease progression either on or following the last dose of the prior regimen for epithelial ovarian, primary peritoneal, or fallopian tube cancer * Subjects must have had one prior platinum-based chemotherapeutic regimen for management of primary disease containing carboplatin, cisplatin, or another organoplatinum compound. * Female 18 years of age or older at the time the written informed consent is obtained * Adequate organ and hematological function Exclusion Criteria: * Subjects who have received more than 3 previous regimens of anti cancer therapy for epithelial ovarian, primary peritoneal or fallopian tube cancer * Subjects treated with prior pegylated liposomal doxorubicin (PLD) or any anthracycline-based or mitoxantrone-based chemotherapy * Subjects with primary platinum-refractory disease * Subjects with platinum-free interval (PFI) \> 12 months from their last platinum based therapy * History of central nervous system metastasis * Major surgery within 28 days prior to randomization or still recovering from prior surgery